What We're Reading: Page 387
Industry reads hand-picked by our editors
Jan 20, 2015
-
-
FierceBiotech
Blast from the past: Roche's dalcetrapib, HDL-raising meds could work for some patients
-
Pfizer warns UK MDs: Lyrica is still on patent for pain
-
Flu vaccine only 23% effective this season
-
-
J&J: Women were inappropriately pressured to file pelvic mesh suits
-
-
Pharma stocks plunge as Switzerland discontinues fixed-price peg to euro
-
-
Jan 16, 2015
-
-
AbbVie's Humira/hep C plans, bluebird bio, NIH funding, and even more from JPM15
-
-
Intrexon, Ziopharma invest $100M in MD Anderson cancer immunotherapy tech
-
-
-
Johnson & Johnson to release trial data
-
New Brilinta data supports extending use beyond one year
-
-
FDA approves novel weight-loss device
Jan 15, 2015
Jan 14, 2015
Jan 13, 2015
Jan 12, 2015
-
How one hedge fund manager plans to take on big pharma patents
-
-
-
-
Biogen Idec's novel optical nerve repair therapy shows promise, but only some
-
-
Finally approved: FDA says 'yes' to Impax's Parkinson's drug
-
-
Tensions with pharma run high as UK's Cancer Drugs Fund cuts expenses
-
Novartis seeks FDA approval for two smoker's cough drugs
Jan 09, 2015
-
The first groundbreaking antibiotic in 25 years may literally come out of the ground
-
-
-
Siga ordered to pay $113M to PharmaAthene in smallpox case
-
-
Namenda controversy continues as Actavis awaits court decision
-
-
-
Study reveals no Gardasil-MS link
-
Novartis OTC advertising under fire after Pfizer complaint
Previous
